Israel · Delayed Price · Currency is ILS · Price in ILA Ilex Medical Statistics
Total Valuation
Ilex Medical has a market cap or net worth of ILS 561.98 million. The enterprise value is 394.47 million.
| Market Cap | 561.98M |
| Enterprise Value | 394.47M |
Important Dates
The next estimated earnings date is Monday, August 24, 2026.
| Earnings Date | Aug 24, 2026 |
| Ex-Dividend Date | Apr 10, 2026 |
Share Statistics
Ilex Medical has 11.19 million shares outstanding. The number of shares has decreased by -0.40% in one year.
| Current Share Class | 11.19M |
| Shares Outstanding | 11.19M |
| Shares Change (YoY) | -0.40% |
| Shares Change (QoQ) | -0.18% |
| Owned by Insiders (%) | 62.77% |
| Owned by Institutions (%) | 12.97% |
| Float | 2.84M |
Valuation Ratios
The trailing PE ratio is 10.92.
| PE Ratio | 10.92 |
| Forward PE | n/a |
| PS Ratio | 0.62 |
| PB Ratio | 0.84 |
| P/TBV Ratio | 0.87 |
| P/FCF Ratio | 9.51 |
| P/OCF Ratio | 6.73 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 4.66, with an EV/FCF ratio of 6.68.
| EV / Earnings | 7.68 |
| EV / Sales | 0.44 |
| EV / EBITDA | 4.66 |
| EV / EBIT | 10.69 |
| EV / FCF | 6.68 |
Financial Position
The company has a current ratio of 2.92, with a Debt / Equity ratio of 0.07.
| Current Ratio | 2.92 |
| Quick Ratio | 2.05 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | 0.51 |
| Debt / FCF | 0.83 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is 7.82% and return on invested capital (ROIC) is 7.18%.
| Return on Equity (ROE) | 7.82% |
| Return on Assets (ROA) | 3.07% |
| Return on Invested Capital (ROIC) | 7.18% |
| Return on Capital Employed (ROCE) | 6.44% |
| Weighted Average Cost of Capital (WACC) | 2.88% |
| Revenue Per Employee | 5.01M |
| Profits Per Employee | 283,768 |
| Employee Count | 181 |
| Asset Turnover | 0.93 |
| Inventory Turnover | 4.14 |
Taxes
In the past 12 months, Ilex Medical has paid 17.87 million in taxes.
| Income Tax | 17.87M |
| Effective Tax Rate | 25.81% |
Stock Price Statistics
The stock price has decreased by -18.35% in the last 52 weeks. The beta is -0.20, so Ilex Medical's price volatility has been lower than the market average.
| Beta (5Y) | -0.20 |
| 52-Week Price Change | -18.35% |
| 50-Day Moving Average | 5,406.34 |
| 200-Day Moving Average | 6,120.99 |
| Relative Strength Index (RSI) | 43.65 |
| Average Volume (20 Days) | 10,790 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Ilex Medical had revenue of ILS 906.15 million and earned 51.36 million in profits. Earnings per share was 4.60.
| Revenue | 906.15M |
| Gross Profit | 205.61M |
| Operating Income | 48.16M |
| Pretax Income | 69.23M |
| Net Income | 51.36M |
| EBITDA | 81.72M |
| EBIT | 48.16M |
| Earnings Per Share (EPS) | 4.60 |
Balance Sheet
The company has 216.70 million in cash and 49.20 million in debt, with a net cash position of 167.51 million or 14.97 per share.
| Cash & Cash Equivalents | 216.70M |
| Total Debt | 49.20M |
| Net Cash | 167.51M |
| Net Cash Per Share | 14.97 |
| Equity (Book Value) | 666.36M |
| Book Value Per Share | 59.62 |
| Working Capital | 428.35M |
Cash Flow
In the last 12 months, operating cash flow was 83.56 million and capital expenditures -24.46 million, giving a free cash flow of 59.10 million.
| Operating Cash Flow | 83.56M |
| Capital Expenditures | -24.46M |
| Depreciation & Amortization | 33.56M |
| Net Borrowing | -14.14M |
| Free Cash Flow | 59.10M |
| FCF Per Share | 5.28 |
Margins
Gross margin is 22.69%, with operating and profit margins of 5.31% and 5.67%.
| Gross Margin | 22.69% |
| Operating Margin | 5.31% |
| Pretax Margin | 7.64% |
| Profit Margin | 5.67% |
| EBITDA Margin | 9.02% |
| EBIT Margin | 5.31% |
| FCF Margin | 6.52% |
Dividends & Yields
This stock pays an annual dividend of 1.99, which amounts to a dividend yield of 3.98%.
| Dividend Per Share | 1.99 |
| Dividend Yield | 3.98% |
| Dividend Growth (YoY) | 62.87% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 26.56% |
| Buyback Yield | 0.40% |
| Shareholder Yield | 4.38% |
| Earnings Yield | 9.14% |
| FCF Yield | 10.52% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on August 21, 2000. It was a forward split with a ratio of 9.
| Last Split Date | Aug 21, 2000 |
| Split Type | Forward |
| Split Ratio | 9 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 5 |